Previous 10 | Next 10 |
Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...
Gainers: SCWorx (NASDAQ:WORX) +28%, Aurinia Pharmaceuticals (NASDAQ:AUPH) +21%, BeyondSpring (NASDAQ:BYSI) +13%, Intersect ENT (NASDAQ:XENT) +12%, Caribou Biosciences (NASDAQ:CRBU) +11%. Losers: Dicerna Pharmaceuticals (NASDAQ:DRNA) -35%, iCAD (NAS...
Spectrum Pharmaceuticals SPPI -35% after FDA declines to approve ROLONTIS Dicerna Pharmaceuticals DRNA -28% slide despite pivotal nedosiran study hitting primary endpoint Zynga ZNGA -16% on Q2 earnings release Chembio Diagnostics CEMI -13% on Q2 earning...
Dicerna Pharmaceuticals (NASDAQ:DRNA) shares have slid more than 30% post-market despite meeting the primary endpoint in a pivotaql trial of nedosiran in patients with primary hyperoxaluria (PH). The likely reason for the decline is that urinary oxalate ((Uox)) excre...
– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants – – Nedosiran Was Generally Well ...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results be...
– Novel ALDH2- Targeting GalXC™ RNAi Candidate Designed to Address a Highly Prevalent and Undertreated Disorder 1 – – Dicerna Expects to Initiate Phase 1 Clinical Trial of DCR-AUD in the Third Quarter of 2021 – Dicerna...
alexsl/iStock via Getty Images Having closed at the highest level since early 2014 on Tuesday, Dicerna Pharmaceuticals (DRNA) dropped ~3.8% today after the company announced interim data for belcesiran in Alpha-1 antitrypsin deficiency-associated liver disease ((AATLD)). D...
– Interim Results From Phase 1 Study Enabled Initiation and First Patient Dosing in Phase 2 ESTRELLA Study, Which Is Currently Underway – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading develo...
Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...